#ASCO22 Myeloma Abstracts - 2022 ASCO Annual Meeting: JUNE 3-7, 2022 Chicago, IL

#EHA2022 - Myeloma Abstracts - EHA2022 Congress: June 9 - 12, 2022 - Vienna, Austria

#COMY22 - Myeloma Abstracts - COMy World Congress Paris, France - May 12-15, 22

IMF - International Myeloma Foundation: Patient Handbook 2022

NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma

FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj(Darzalex Faspro) + Kyprolis & Dexamethasone

NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

What are Multiple myeloma defining events? International Myeloma Working Group - SLiM-CRAB Criteria

NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5

NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma - NUTRIVENTION

NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma

NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM

NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM

What is Multiple Myeloma? - Drs. Landgren and Gertz HealthTree University Myeloma

NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population

NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM

NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.